Open AccessClinical Outcome of Patients on Ceftazidime–Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae
Author(s) -
Vasant Nagvekar,
Anand Shah,
Vrajeshkumar P Unadkat,
Amol Chavan,
Ruhi Kohli,
Shailendra Hodgar,
Aashita Ashpalia,
Niranjan Patil,
Rahul D. Kamble
Publication year - 2021
Publication title -
indian journal of critical care medicine/indian journal of critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 30
eISSN - 1998-359X
pISSN - 0972-5229
DOI - 10.5005/jp-journals-10071-23863
Subject(s) - medicine , aztreonam , ceftazidime/avibactam , ceftazidime , carbapenem resistant enterobacteriaceae , carbapenem , avibactam , beta lactamase inhibitors , klebsiella pneumoniae , enterobacteriaceae , antibiotics , cephalosporin , intensive care medicine , microbiology and biotechnology , antibiotic resistance , imipenem , pseudomonas aeruginosa , biology , escherichia coli , bacteria , biochemistry , genetics , gene
Carbapenem-resistant Enterobacteriaceae (CRE) infections have a major effect on mortality as well as healthcare cost. Intensive care units (ICUs) in India, the epicenters for multidrug-resistant organisms, are facing a "postantibiotic era" because of very limited treatment options. A latest beta-lactam/beta-lactamase inhibitor ceftazidime-avibactam (CZA) new has a broad-spectrum antibacterial activity. CZA inhibits class-A and class-C beta-lactamases (as well Klebsiella pneumoniae carbapenemase (KPC)), along with some class-D carbapenems such as OXA-48 -like enzymes that are seen in Enterobacteriaceae has recently become available. The current study aimed to assess and present the clinical response and patient outcome with infections due to CRE when treated with CZA alone or in combination with other drugs.